Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis
Aleksander Bogdański(Leiden University Medical Center), the Dutch Pancreatic Cancer Group, Michael B. Wallace(Jacksonville College), Derk C.F. Klatte(Leiden University Medical Center), Mariëtte C.A. van Kouwen(Radboud University Nijmegen), Evelien Dekker(Academic Medical Center), Lodewijk A.A. Brosens(Utrecht University), Tanya M. Bisseling(Radboud University Nijmegen), Bert A. Bonsing(Leiden University Medical Center), Maartje Nielsen(University Medical Center Groningen), Monique E. van Leerdam(Leiden University Medical Center), Douglas L. Riegert‐Johnson(Jacksonville College), Jeanin E. van Hooft(Leiden University Medical Center), Lydia G. van der Geest(Netherlands Comprehensive Cancer Organisation), Barbara A.J. Bastiaansen, Ananya Das(Chittaranjan National Cancer Institute), Sobia I. Laghari(Leiden University Medical Center), Jewel N. Samadder(Mayo Clinic in Arizona), Lisa Boardman(Mayo Clinic in Arizona), Alexandra M. J. Langers(Leiden University Medical Center)
Cited by 1
Related Papers
Colorectal cancer
|The Lancet|2019|5k
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
|Endoscopy|2019|846